Hyperbaric oxygen therapy can reverse sudden vision loss from CRAO
Hyperbaric oxygen therapy can reverse sudden vision loss from CRAO
Understanding CRAO and why immediate hyperbaric oxygen treatment can save your vision
Central retinal artery occlusion (CRAO) occurs when the main artery supplying blood to the retina becomes blocked, typically by a blood clot, plaque buildup or inflammation. This causes sudden, painless vision loss in one eye that is often permanent without immediate treatment. The retina is one of the most metabolically active tissues in the body and can suffer irreversible damage within hours of losing its blood supply.
HBOT provides a unique solution by delivering oxygen to the retina through an alternative pathway. Under hyperbaric pressure, oxygen dissolves directly into plasma at concentrations high enough to sustain retinal tissue even when the artery is blocked. This buys critical time for the clot to resolve while preserving viable retinal cells. Clinical studies show significant improvements in visual acuity and reduced risk of neovascular glaucoma when HBOT is administered promptly.
Sudden painless vision loss in one eye
Partial or complete loss of visual field
Risk of permanent retinal damage within hours
Potential development of neovascular glaucoma
How pressurized oxygen bypasses the blocked artery to save your vision
HBOT delivers oxygen to the retina through plasma diffusion, providing the only way to oxygenate retinal tissue when the artery is blocked.
Delivers oxygen directly to the retina and retinal artery
Improves retinal blood flow
Reduces inflammation around retinal arteries
Promotes new blood vessel growth for long-term recovery
Reduces risk of neovascular glaucoma
Preserves retinal tissue during the critical window
For Providers
Clinical evidence for HBOT in central retinal artery occlusion
Hyperbaric oxygen therapy for CRAO is supported by clinical evidence demonstrating significant improvements in visual outcomes when treatment is administered promptly.
Oxygen delivery mechanism: HBOT provides concentrated oxygen under pressure, enhancing oxygen supply to the retina by circumventing the obstructed artery. Under hyperbaric conditions, oxygen dissolves into plasma at concentrations sufficient to sustain retinal metabolism through diffusion from surrounding choroidal circulation, even when the central retinal artery is completely blocked.
Neovascularization: HBOT encourages the development of new blood vessels by activating hypoxia-inducible factors (HIFs). This stimulated angiogenesis supports long-term retinal vascular recovery beyond the acute occlusion event.
Anti-inflammatory effects: HBOT reduces inflammation by diminishing the production of inflammatory cytokines and promoting anti-inflammatory mediators. This addresses the vascular inflammation that often contributes to the occlusion and prevents secondary inflammatory damage to retinal tissue.
Clinical outcomes: Studies published in Scientific Reports and Retina-Vitreus Journal demonstrate that HBOT achieves significant improvements in visual acuity in CRAO patients. Combined treatment approaches (HBOT with anterior chamber paracentesis) show particularly strong outcomes. Research also confirms reduced risks of neovascular glaucoma when HBOT is part of the treatment protocol.
Time-critical treatment: The retina can suffer irreversible damage within hours of losing its blood supply. HBOT is most effective when initiated within 24 hours of vision loss onset. Every hour of delay reduces the amount of viable retinal tissue that can be saved.
Hyperbaric oxygen therapy for combined branch retinal artery and branch retinal vein occlusion
Hyperbaric oxygen therapy significantly improves best-corrected visual acuity and preserves retinal structure in central retinal artery occlusion patients, when initiated within 7 days of symptom onset, underscoring its potential to enhance visual outcomes and retinal integrity.
This study evaluated the efficacy of hyperbaric oxygen therapy in patients with central retinal artery occlusion by assessing changes in visual acuity and retinal thickness using enhanced depth imaging optical coherence tomography. A retrospective review included 50 eyes from 50 patients, with 29 eyes receiving HBO treatment within 7 days of symptom onset and 21 eyes serving as controls. At 6-month follow-up, the HBOT group showed a significant improvement in best-corrected visual acuity, while the control group showed no change. Additionally, the HBOT group exhibited significant increases in central choroidal thickness and outer retinal layer thickness, suggesting that HBOT preserves retinal structure. These findings support the potential of HBOT to improve visual outcomes and retinal integrity in CRAO patients. Lee JM, Choi SH, Jeon GS, Chang IB, Wang SJ, Hong IH. A comprehensive evaluation of efficacy of hyperbaric oxygen therapy in non-arteritic central retinal artery occlusion using enhanced depth imaging optical coherence tomography. Scientific Reports. 2024;14(1):1-8. doi:10.1038/s41598-024-71895-1Hyperbaric oxygen therapy for non-arteritic central retinal artery occlusion: efficacy of combined treatment with anterior chamber paracentesis
Combining hyperbaric oxygen therapy with anterior chamber paracentesis significantly improves visual acuity in central retinal artery occlusion compared to HBOT or ACP alone, emphasizing the potential benefit of early multimodal intervention.
A 5+ year retrospective review of CRAO patients compared the effects of hyperbaric oxygen therapy and anterior chamber paracentesis on visual acuity. Thirty-four patients were divided into three groups: HBOT with ACP, HBOT alone, and ACP alone. Baseline VA across groups was similar. At the final follow-up, only Group 1 showed a significant VA improvement from baseline, while Groups 2 and 3 exhibited no significant changes. These findings suggest that combining HBOT with ACP may enhance visual recovery in CRAO, particularly when initiated promptly. Yucel OE, Bodur MF, Yucel SM. Hyperbaric oxygen therapy for non-arteritic central retinal artery occlusion: efficacy of combined treatment with anterior chamber paracentesis. Retina-Vitreus/Journal of Retina-Vitreous. 2024;33(2):117-122. doi:10.37845/ret.vit.2024.33.18Hyperbaric Oxygen Therapy in Retinal Arterial Occlusion: Epidemiology, Clinical Approach, and Visual Outcomes
Hyperbaric oxygen therapy is a safe and effective early intervention for retinal artery occlusion, significantly improving best-corrected visual acuity in a majority of cases, with no reported complications and a median treatment initiation within 9 hours of symptom onset.
Retrospective study of 13 patients submitted to HBOT between 2013 and 2018. The analysed parameters consisted of: systemic history, time between symptoms onset and treatment, initial approach, number of HBOT sessions, complications of HBOT and best corrected visual acuity—BCVA (of the total sample, central RAO—CRAO—group, and branch RAO—BRAO group). Results. Arterial hypertension was the most prevalent systemic risk factor (53.8%). Initial therapies were 100% normobaric oxygen administration, topical and oral hypotensive medication, eye massage and aspirin. CRAO was observed in 69.2% and BRAO in 30.8% of the cases, with clinically significant visual improvement (a decrease in logMAR of 0.3) in 55.5% and 75%, respectively. Time between symptoms onset and treatment had a median of 9 hours. The median number of HBOT sessions was 7, without complications. Conclusions. HBOT provide BCVA improvement in patients with RAO, when it is performed in an early time after the symptom onset. It seems to be an effective and safe therapeutic option for a pathology that still remains without approved treatment. Lopes AS, Basto R, Henriques S, et al. Hyperbaric Oxygen Therapy in Retinal Arterial Occlusion: Epidemiology, Clinical Approach, and Visual Outcomes. Case Reports in Ophthalmological Medicine. December 2019:1-6. doi:10.1155/2019/9765938Vision recovery experiences
Lisa, 44
Jennifer, 68
Emergency treatment protocol for retinal artery occlusion
CRAO is an eye emergency. Go to the ER immediately and demand they approve hyperbaric treatment within 24 hours.
Emergency assessment and immediate HBOT initiation
Time is critical. Our medical team coordinates with your ophthalmologist to begin HBOT as quickly as possible. Treatment within 24 hours gives the best chance for vision recovery.
HBOT sessions to oxygenate the retina
You breathe 100% oxygen at increased atmospheric pressure for 90 minutes per session. Acute CRAO may require multiple sessions in the first 24-48 hours.
Vision monitoring and continued treatment
We track visual acuity improvement and coordinate with your ophthalmologist. Additional sessions support ongoing retinal recovery and reduce complication risk.
Frequently Asked Questions
Answers to the questions patients ask most about hyperbaric oxygen therapy for retinal artery occlusion and sudden vision loss.
Immediately. CRAO is an eye emergency — the retina can suffer permanent damage within hours. Go to the emergency room right away and require them to approve hyperbaric treatment. Treatment within 24 hours provides the best chance for vision recovery.
Sudden vision loss? This is an emergency
Go to the ER immediately, then call Bay Area Hyperbarics. HBOT within 24 hours is your best chance to save your vision.
